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ABSTRACT
Cell secretion is an importantmechanism for stemcell-based therapeutic angiogenesis, alongwith cell
differentiation to vascular endothelial cells or smoothmuscle cells. Cell-releasedmicrovesicles (MVs)
havebeen recently implicated toplay anessential role in intercellular communication. Thepurposeof
this studywas toexplore thepotential effects of stemcell-releasedMVs inproangiogenic therapy.We
observed for the first time that MVs were released from adipose-derived stem cells (ASCs) and were
able to increase themigration and tube formationof humanumbilical vein endothelial cells (HUVECs).
Endothelial differentiation medium (EDM) preconditioning of ASCs upregulated the release of MVs
andenhanced theangiogenic effectof the releasedMVs in vitro. RNAanalysis revealed thatmicroRNA
was enriched in ASC-released MVs and that the level of microRNA-31 (miR-31) in MVs was notably
elevated upon EDM-preconditioning of MV-donor ASCs. Further studies exhibited that miR-31 in
MVs contributed to the migration and tube formation of HUVECs, microvessel outgrowth of mouse
aortic rings, and vascular formation of mouse Matrigel plugs. Moreover, factor-inhibiting HIF-1, an
antiangiogenic gene, was identified as the target of miR-31 in HUVECs. Our findings provide the first
evidence that MVs from ASCs, particularly from EDM-preconditioned ASCs, promote angiogenesis
and the delivery of miR-31 may contribute the proangiogenic effect. STEM CELLS TRANSLATIONAL
MEDICINE 2016;5:440–450
SIGNIFICANCE
This study provides the evidence that microvesicles (MVs) from adipose-derived stem cells (ASCs),
particularly from endothelial differentiation medium (EDM)-preconditioned ASCs, promote angio-
genesis. An underlying mechanism of the proangiogenesis may be the delivery of microRNA-31
via MVs from ASCs to vascular endothelial cells in which factor-inhibiting HIF-1 is targeted and sup-
pressed. The study findings reveal the roleofMVs inmediatingASC-inducedangiogenesis and suggest
a potential MV-based angiogenic therapy for ischemic diseases.
INTRODUCTION
Ischemic cardio- and cerebrovascular diseases
continue to represent a critical and growing cause
of morbidity and mortality despite the significant
advances in medical, interventional, and surgical
therapies for these cases. To address these con-
cerns, the science of therapeutic angiogenesis
has been evolving for the past 2 decades [1].
Theprotein/gene approach, including growth fac-
tors and cytokines, and the subsequent stem/
progenitor cell approach have been extensively
investigated in the therapy for ischemic heart dis-
ease [2, 3]. Adipose-derived stem cells (ASCs) are
an attractive vehicle for cell-based therapeutics,
with advantages of easy acquisition, as well as
more proliferative potential and less histocom-
patibility antigen [4]. It has been reported that
ASCs either originate from [5] or can assume
the role of [6, 7] pericytes during treatment of
the microvasculature. Implantation of ASCs, par-
ticularly endothelial differentiation medium
(EDM)-preconditioned ASCs, is beneficial to an-
giogenesis in ischemic limb and heart models.
Mechanistic studies have revealed that a signifi-
cant proportion of beneficial effects of ASC ad-
ministration may be due to secretion rather
than endothelial differentiation of ASC [8–10].
Apart from soluble growth factors, cell-released
microvesicles (MVs)/exosomes have been recog-
nized recently as a new mechanism of intercellu-
lar communication [11].
MVs are plasma membrane-derived vesicles
that are released into the microenvironment by
various cell types, including stem cells and pro-
genitors. Unlike protein molecules or living cells,
MVs are submicron particles that target recipient
cells to deliver proteins and lipids, and, therefore,
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trigger downstream signaling events at distant locations through-
out the body [12]. An emerging MV/exosome approach of ther-
apeutic angiogenesis may present a promising outlook for
ischemic diseases [13–17]. This approach, in comparison with
the stem/progenitor cell approach, avoids thepossibility of tumor
formation due to uncontrolled cell proliferation and microvascu-
lature occlusion upon intra-arterial administration of implanted
cells [3]. Additionally, in the treatment of ischemic heart diseases,
MV-based strategy may avoid the proarrhythmic risk due to im-
mature phenotype and syncytium formation, and may avoid
myocardial ossification and/or calcification resulting from chon-
drocyte and osteocyte differentiation caused by cell-based para-
digms [18]. Recent studies have shown that MVs deliver genetic
material, mRNA and microRNA (miRNA), and thus play a critical
role inmodulating the function of target cells [19–24]. Indeed, se-
cretion ofMVs has been proved tomediate the angiogenic poten-
tial of tumor cells [25]. Further investigations have provided the
evidence that MVs released from endothelial progenitor cells or
bone marrow mesenchymal stem cells can directly promote an-
giogenesis in vitro and in vivo [20, 26–28]. However, the underly-
ing molecular mechanisms remain poorly understood. In the
current study, we demonstrate that ASC-released MVs promote
angiogenesis. TheMVs are enrichedwithmiRNA, inwhichmiR-31
may contribute to the induction of angiogenesis by targeting FIH1
(factor-inhibiting HIF-1) in recipient endothelial cells.
MATERIALS AND METHODS
Cell Culture
Human ASCs (Thermo Fisher Scientific, Carlsbad, CA, https://
www.thermofisher.com) and human umbilical vein endothelial
cells (HUVECs) (Thermo Fisher Scientific) were maintained in
ASC growth medium and endothelial cell growth medium (both
Thermo Fisher Scientific), respectively, in a humidified atmo-
sphere of 5% CO2 and 95% air at 37°C, according to the manufac-
turer’s instructions. The medium was replaced every 2–3 days,
and passages 3–4 were used for all experiments.
EDM Preconditioning and Conditioned Medium
Preparation of ASCs
ASCs were pretreated with EDM (PromoCell, Heidelberg, Ger-
many, http://www.promocell.com) containing endothelial basal
medium supplemented with 2% fetal bovine serum (FBS), 5 ng/
ml epidermal growth factor, 10 ng/ml basic fibroblast growth fac-
tor, 20 ng/ml insulin-like growth factor, 1 mg/ml ascorbic acid,
22.5mg/ml heparin, 0.2mg/ml hydrocortisone, 50 ng/ml vascular
endothelial growth factor, 100 U/ml penicillin, and 100 mg/ml
streptomycin. The same medium was changed once during the
4-day preconditioning period. Cells were then washed with
phosphate-buffered saline (PBS) and incubated in fresh endothe-
lial basal medium/1% MV-free FBS with or without GW4869
(Thermo Fisher Scientific), an inhibitor of MV formation [29],
for an additional 2 days. The culture medium was collected and
centrifuged at 500g for 10 minutes at 4°C to remove untouched
cells. Supernatant was used as conditioned medium (CdM).
The CdM with removal of MVs via sequential centrifugations
of CdM at 12,000g for 30 minutes and ultracentrifugation
(Beckman Coulter L8-80M Ultracentrifuge; Brea, CA, https://
www.beckmancoulter.com) at 100,000g for 60 minutes at 4°C
was used as CdM-MV free. CdM or CdM-MV free, mixed with
an equal volume of fresh endothelial basal medium/1% FBS,
was used for HUVEC angiogenic analysis. Endothelial basal
medium/1% FBS without cells was incubated in parallel for 2
days, mixed with equal amounts of fresh endothelial basal
medium/1% FBS, and used as the control. All of the FBS used
in this study was MV-free FBS, achieved by ultracentrifugation
of FBS at 100,000g for 60 minutes at 4°C.
Preparation of MVs
MVs were isolated by sequential centrifugations of the ASC cul-
ture medium at 500g for 10 minutes, 12,000g for 30 minutes,
and 100,000g for 60 minutes at 4°C. The supernatant was dis-
carded. To remove residual soluble factors, pelleted MVs were
then washed with PBS once by centrifugation at 100,000g for
60 minutes at 4°C, as described previously [30]. MVs were resus-
pended in indicated buffer or endothelial basal medium/1% FBS
for subsequent analysis or angiogenic assay. The protein concen-
trationofMVswasmeasuredusing aNanoDrop1000 spectropho-
tometer (Thermo Fisher Scientific). In this report, MVs from ASCs
preconditioned with EDM are designated as MV-P.
Cell Migration Assay
HUVEC migration was estimated by a quantitative cell-migration
assay that combined the use of membrane-based Boyden cham-
bers, propidium iodide (EMD Chemicals, Gibbstown, NJ, http://
www.emdmillipore.com) staining, and software-assisted count-
ing of nuclei of migrated cells, as described in our previous report
with slight modification [31]. In brief, HUVECs were treated with
various CdM, orwithMVs at 30mg/ml (protein concentration) for
24 hours, or transfected as described below. The treated HUVECs
in endothelial basal medium/1% FBS were then seeded in a 96-
well transwell plate (BD Biosciences) at 1.25 3 104 per insert
(3-mm pores). Endothelial basal medium/1% MV-free FBS was
added to the upper and lower compartment of thewell, followed
by incubation at 37°C in 5% CO2 for 24 hours. The HUVECs were
then fixed in absolute ethanol and stainedwith propidium iodide.
The cells that migrated to the lower side of the inserts were
counted.
Tube Formation Assay
HUVECs were treated with various CdM, or withMVs at 30mg/ml
(protein concentration) for 24 hours, or transfected as described
below. The treated HUVECs in endothelial basal medium/1% FBS
were seeded in a 96-well plate at 13 104 per well precoatedwith
growth factor-reduced Matrigel (BD Biosciences). The plate was
then incubated at 37°C in 5% CO2 for 4 hours. The cells were
stained with 10 mM Calcein AM (Thermo Fisher Scientific) at
37°C in 5% CO2 for 30minutes. Tube formation was checked with
an inverted fluorescence microscope (Olympus IX71; Olympus,
Tokyo, Japan, http://www.olympus-global.com), and tube length
was calculated using ImagePro Plus software (MediaCybernetics,
Rockville, MD, http://www.mediacy.com).
Electron Microscopy
MVswere fixed in 2.5%glutaraldehyde and 1%osmium tetroxide,
dehydrated in alcohol, dried on a glass surface, and coated with
gold using sputter coating. MV slides were then examined in a
scanning electron microscope (JSM-820; JEOL, Tokyo, Japan,
http://www.jeol.co.jp). Images were obtained by secondary
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electron microscopy at a working distance of 8 mm and an accel-
erating voltage of 10 kV.
Immunoblotting
Western blot for cells or MVs was performed as previously de-
scribed [32]. Cellswere lysed inmammalian protein extraction re-
agent (Thermo Fisher Scientific) supplemented with a protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, http://www.
sigmaaldrich.com). The cell lysates were resolved by electropho-
resis on 4%–12% precast Bis-Tris gel (Thermo Fisher Scientific).
Proteins were transferred from the gel to a nitrocellulose mem-
brane using an iBlot Dry Blotting System (Thermo Fisher Scien-
tific). Specific proteins were detected using primary antibodies,
anti-Alix (ab88743; Abcam, Cambridge, MA, http://www.
abcam.com), anti-FIH1 (AV32903; Sigma-Aldrich), and anti-b-ac-
tin (sc-47778; Santa Cruz Biotechnology, Santa Cruz, CA, http://
www.scbt.com). Alix is an exosome-associated protein involved
in multivesicular endosome biogenesis [12, 33].
Cell Proliferation Assay
HUVECs were seeded in a 96-well plate at 7.53 103 cells per well
and were quiesced with endothelial basal medium/1% FBS for 24
hours. Cellswere then treatedwith variousMVs at 30mg/ml (pro-
tein concentration) for 3 days. Untreated cellswereused as a con-
trol. A Cell Counting Kit-8 (Dojindo Molecular Technologies,
Rockville, MD, http://www.dojindo.com) was used for the cell
proliferation assay. An absorbance spectrum at 450 nm was
recordedwith a spectrophotometer (SpectraMAX190;Molecular
Devices; Sunnyvale, CA, http://www.moleculardevices.com). En-
dothelial basalmedium/1%FBS incubated inparallelwithout cells
was used as the background.
Extraction of RNA
Extraction of total RNA, small RNA (fewer than 200 nucleotides),
and large RNA from ASCs or MVs was performed using a mirVana
isolation kit (Thermo Fisher Scientific) according to the manufac-
turer’s instructions and our previous description [32]. The con-
centration of RNA was determined using the NanoDrop 1000
spectrophotometer.
RNA Analysis With Bioanalyzer
An Agilent 2100 Bioanalyzer (Agilent Technologies; Santa Clara,
CA, http://www.agilent.com) was used following the manufac-
turer’s protocol. Total RNA (20ng) fromMVsand fromtheir donor
ASCswas analyzedwith an Agilent RNA 6000Nano kit and an RNA
6000 ladder, and 20 ng of small RNA fromMVswas analyzed with
an Agilent Small RNA kit (all Agilent Technologies).
TaqMan miRNA Assay
Reverse transcription of 10 ng of small RNA from MVs was per-
formed using a specific miRNA primer from the corresponding
TaqManMicroRNAAssay and reagents fromaTaqManMicroRNA
Reverse Transcription Kit (Thermo Fisher Scientific). Transcribed
complementary DNAs (cDNAs) were subsequently preamplified
using theTaqManMicroRNAAssayand theTaqManPreAmpMas-
terMix (Thermo Fisher Scientific) according to themanufacture’s
protocol. Reverse-transcriptase-polymerase chain reaction (RT-
PCR) was carried out using the diluted preamplified products,
the specific TaqMan MicroRNA Assays, and a TaqMan Universal
PCR Master Mix (Thermo Fisher Scientific), as described previ-
ously [32]. The relative miRNA levels were normalized to endog-
enous U6 small nuclear RNA, a highly conserved small nuclear
RNA in vertebrate genomes, for each sample.
Creation and Transduction of Recombinant Lentivirus
The procedures practiced here followed the National Institutes
of Health guidelines for recombinant DNA research. To deplete
the expression of miR-31 in ASCs, a lentiviral Lenti/ZIPmiR-31
(ZIPmiR-31) and a control, Lenti/ZIPmiR-Cont (ZIPmiR-Cont),
were created using commercial plasmids pLenti/ZIPmiR-31 and
pLenti/ZIPmiR-Cont (System Biosciences, Mountain View, CA,
https://www.systembio.com), respectively. To test the targeting
activity of miR-31, a full-length (1–5,787 base pairs) and a half-
length (1–2,681 base pairs) of 39 untranslated region (39-UTR)
of FIH1 were each cloned into a luciferase reporter plasmid (Ap-
plied Biological Materials, Richmond, British Columbia, Canada,
https://www.abmgood.com), and designated pLenti/UTR-Luc/
FIH1-FL and pLenti/UTR-Luc/FIH1-HL, respectively. Meanwhile,
a plasmid containing a mutated half-length of FIH1 39-UTR,
pLenti/UTR-Luc/FIH1-HLmut, was generated by replacing the nu-
cleotides UCUUGC with AAGCUU at the predicted miR-31 target
site 117–124 [34]. Then, the lentiviral Lenti/UTR-Luc/FIH1-FL
(Luc/FIH1-FL), Lenti/UTR-Luc/FIH1-HL (Luc/FIH1-HL), and Lenti/
UTR-Luc/FIH1-HLmut (Luc/FIH1-HLmut) were created using the
above plasmids. A lentiviral Lenti/UTR-Luc/Blank (Luc/Blank)
was used as a control. ASCs were transduced with ZIPmiR-Cont
or ZIPmiR-31at amultiplicity of infection (MOI)of 2.HUVECswere
transducedwith Luc-UTR/Blank, Luc-UTR/FIH1-FL, Luc-UTR/FIH1-
HL, or Luc-UTR/FIH1-HLmut at an MOI of 1. The detailed methods
of lentiviral creation, concentration, titration, and transduction
were described previously [32, 35].
Cell Transfection
Lipofectamine RNAiMAX (Thermo Fisher Scientific) was used for
HUVEC transfection according to themanufacturer’s instructions.
Transfection of 10 nM pre-miR-Cont or pre-miR-31 (Thermo
Fisher Scientific) was performed in the HUVECs. The transfection
medium was changed to regular endothelial cell growth medium
6 hours later. The cells were then incubated to recover for an ad-
ditional 42hours for subsequent cellmigration assay, tube forma-
tion assay, RT-PCR analysis, or incubated overnight for lentiviral
transduction and luciferase activity assay.
Aortic Ring Assay
All animal experiments in this study were approved by the Insti-
tutional Animal Care andUseCommittee of theAtlantaUniversity
Center (approval no. 13-09) and compliedwith theNIH guidelines
for the careanduseof laboratory animals. Anaortic ringassaywas
performed according to previous reports [36–39].Male C57BL/6J
mice at age 8–10 weeks were obtained from The Jackson Labora-
tory (Bar Harbor, ME, https://www.jax.org) and were euthanized
with CO2 inhalation. Aortae were collected, cleaned, and cut into
rings approximately 0.5-mmwide under sterile conditions. Aortic
rings were transferred to a 96-well plate at 8 rings per well and
incubated with the indicated MVs at 100 mg/ml (protein concen-
tration) in Opti-MEM (Thermo Fisher Scientific) overnight. Each
ringwas thenembedded in 50ml ofMatrigel in an8-well Chamber
Slide (Thermo Fisher Scientific) at 1 ring per well and incubated in
300 ml per well of Opti-MEM supplemented with 2.5% FBS. The
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mediumwas carefully changed 3 days after embedding. At day 5,
the rings were stainedwith 10mMCalcein AMat 37°C for 30min-
utes. The chamber was removed and a coverslip was placed to
cover the slide. Z-stack images were taken with a fluorescent mi-
croscope (Olympus BX41) equipped with a camera (Olympus
DP70) and cellSens digital imaging software (Olympus). Out-
growth area was determined with ImagePro Plus software
(MediaCybernetics).
Matrigel Plug Assay
Ice-cold Matrigel (300 ml per plug) was mixed with PBS or MVs
(100 mg per plug) and then injected subcutaneously into the
flanksofmalenudemice, 6–8weeksold (The Jackson Laboratory).
The mice were euthanized with CO2 inhalation 2 weeks after im-
plantation. The entireMatrigel plugs were excised, then weighed
and frozen for immunohistochemistry.
Immunohistochemistry
Matrigelplugswereembedded inoptimal cutting temperaturecom-
pound (Sakura, The Netherlands, http://www.sakura.eu) and snap-
frozen by immersing in liquid nitrogen-cooled 2-methylbutane
(Sigma-Aldrich). The frozen blocks were cryosectioned at a thick-
ness of 10 mm with a microtome cryostat (Leica Microsystems,
Buffalo Grove, IL, http://www.leica-microsystems.com). The sec-
tion was mounted onto a glass slide. The slides were dried at
room temperature for 2 hours and fixed in cold methanol at
220°C for 15minutes. The slides were then dried in a fume hood
for 30minutes andwashedwith PBS twice. EachPBSwashing step
lasted 5 minutes. After blockade with 3% bovine serum albumin
(BSA) in PBS at room temperature for 1 hour, primary anti-CD31
antibody (558736; BD Biosciences) was added to each section
at a dilution of 1:200 in blocking buffer and incubated at 4°C
overnight. The slides were washed with PBS 3 times and incu-
bated with secondary Alexa Fluor 488 donkey anti-rat IgG
(Thermo Fisher Scientific) at a dilution of 1:500 in blocking
buffer at room temperature for 1 hour. The slides were then
washed with PBS once, counterstained with 49,6-diamidino-
2-phenylindole (DAPI; Thermo Fisher Scientific) at a dilution
of 1:5,000 for 3 minutes, and washed with PBS twice. Aqueous
mountingmedium (ElectronMicroscopy Sciences, Hatfield, PA,
https://www.emsdiasum.com) was added for mounting with a
coverslip. The images were acquired using a digital camera-
equipped fluorescence microscope. The regions containing
the most intense CD31+ areas of neovascularization (hotspots)
were chosen for quantification. Five hotspots per section and 3
sections per plugwere analyzed at3200magnification. Image-
Pro Plus software (MediaCybernetics) was used to measure
CD31+ areas in each hotspot [27].
Luciferase Reporter Assay
HUVECs were transfected with 10 nM pre-miR-Cont or pre-
miR-31 and then transduced with lentivirus Luc-UTR/Blank,
Luc-UTR/FIH1-FL, Luc-UTR/FIH1-HL, or Luc-UTR/FIH1-HLmut
the next day. Two days after the transduction, luciferase activ-
ities in HUVECs were determined using a Luciferase Assay Kit
(Applied Biological Materials) and a microplate luminometer,
Lmax, equipped with SOFTmax PRO software (Molecular De-
vices), according to manufacturer’s instructions and our previ-
ous report [32].
Real-Time PCR Analysis for mRNA
RNAextraction fromHUVECs, cDNA reverse transcription, andRT-
PCR analysis were performed according to our previous report
[32]. The primer pairs used were 59-taggaccagaagcgagaatg-39
and 59-tcctgcatcggatgtaaaat-39 for human FAT4 [40]; 59-ttcctg-
ctgaacacggtc-39 and 59-cggagcgctgcgtgagct-39 for human TBXA2R
[41]; 59-gaagaagattttcaacctgatgg-39 and 59-gaactcttggctcctttctgc-
39 for human RGS4 [42]; 59-agtggttggccctggtgatgttct-39 and 59-
aagcggtgtggacgggatagcagt-39 for human FIH1; 59-gatgcggctcgt-
cagggggtgta-39 and 59-ggcgtgtttggggatgctgttgtg-39 for human
TIAM1; and 59-gctcgtcgtcgacaacggct-39 and 59-caaacatgatctgggt-
catcttctc-39 for human b-actin.
Endothelial Cell Differentiation of ASCs
ASCswere incubated in EDMfor the indicateddays. CD31andvas-
cular endothelial (VE)-cadherin are endothelial cell markers. The
proportion of CD31 or VE-cadherin positive cells was determined
using immunocytochemistry and flow cytometry analysis. Briefly,
the cells were harvested and stained with anti-CD31 antibody
(Abcam) at 1:100 in 3% BSA/PBS, or anti-VE-cadherin antibody
(Abcam) at 1:50 in 3% BSA/PBS. The cells were incubated in the
primary antibody at room temperature overnight at 4°C in dark-
ness. The cells were washed twice with ice-cold PBS by centrifu-
gation at 400g for 5minutes and then incubated in AF488-labeled
anti-mouse secondary antibody (Thermo Fisher Scientific) diluted
in 3% BSA/PBS at room temperature for 30 minutes in darkness.
The cells were washed twice with PBS and subjected to flow
cytometry analysis. Flow cytometry analysiswas performed using
a Guava EasyCyte System equipped with CytoSoft software (EMD
Millipore, Billerica, MA, http://www.emdmillipore.com). The
ExpressPlus program (De Novo Software, Glendale, CA, https://
www.denovosoftware.com) was selected to perform the analysis.
Statistical Analysis
Results from the quantitative studies were expressed as mean6
SD in triplicate at a minimum. All experiments were indepen-
dently repeated at least four times. Statistical comparisons be-
tween two groups were performed using a two-tailed Student’s
t test. Differences among multiple groups were statistically ana-
lyzed using one-way analysis of variance (ANOVA) and a two-way
ANOVA test for multiple groups with two main treatments, fol-
lowed by post hoc Tukey analysis. Differences were considered
significant when p, .05.
RESULTS
ASC-Released MVs Promoted Migration and Tube
Formation of HUVECs
Although ASCs can be efficiently differentiated to adipocytes [32,
35], our observations in this study demonstrated that incubation
of ASCs in EDM for 10 days induced very little expression of 2 en-
dothelial markers, CD31 and VE-cadherin (supplemental online
Fig. 1). Nevertheless, EDM preconditioning is observed to further
enhance the proangiogenic effects of ASCs via the contribution of
paracrine mediators [8, 9]. To examine whether ASC-released
MVs are an important mediator for angiogenesis, CdM from
EDM-preconditioned ASCs was collected and added to HUVECs
to detect cell migration and tube formation. Our results demon-
strated that HUVECmigration (control: 65.26 11.4 cells; CdM:
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126.66 17.9 cells) and tube formation (control: 1.006 0.28; CdM:
2.3960.22)were inducedbyCdM. The inductionofmigration (CdM-
MV free: 82.46 5.1 cells) and tube formation (CdM-MV free: 1.286
0.13) was significantly reduced when MVs were removed from
CdM (Fig. 1A, 1B). On the other hand, upon inhibiting the gener-
ation ofMVs by the incubation of ASCswithGW4869 [29], themi-
gration (0 mM: 107.26 5.2 cells; 0.1 mM: 96.26 7.2 cells; 1 mM:
88.0 6 3.3 cells; 10 mM: 75.0 6 8.8 cells) and tube formation
(0 mM: 1.00 6 0.09; 0.1 mM: 1.03 6 0.10; 1mM: 0.60 6 0.09; 10
mM: 0.54 6 0.06) effects of CdM were also reduced (Fig. 1C, 1D).
Thesedata implythatMVsareaproangiogenicmediator for theASCs.
MV isolation was performed with the CdM collected from
EDM-preconditioned ASCs. Scanning electron microscopy
showed that the particles in the isolated pellet were unevenly
sized spheroids of less than 1 mm (Fig. 2A), which agrees with
the reported characteristics ofMVs [20]. In addition, thepresence
of Alix, a marker of MV [12, 33], was detected in the isolated
pellet. Moreover, our results exhibited that the preconditioning
ofASCswithEDMmarkedlypromotedMVrelease,whichwaspar-
tially inhibited by GW4869 (MV miRNA level set to 1.00. 0 mM:
6.45; 0.1 mM: 7.45; 1 mM: 5.55; 10 mM: 4.37) (Fig. 2B). Quantifi-
cation of MV protein also demonstrated that EDM enhanced the
MV release fromASCs (MV: 3.56 0.6;MV-P: 17.56 2.8) (Fig. 2C).
Pretreatment of CdMwith detergent, 1%Triton-X100 for 20 min-
utes at 4°C, resulted in a loss of Alix detection, which suggested
that isolated MVs were intact plasma membrane-encapsulated
particles that can be broken down by the detergent (data not
shown). Equal amounts of MV andMV-P were then used to treat
HUVECs. Our data showed that migration (control: 45.3 6 12.8
cells; MV: 127.0 6 14.3 cells) and tube formation (control:
1.006 0.10; MV: 1.676 0.15) of HUVECs were significantly ele-
vated upon the treatment of MVs. Interestingly, MV-P exhibited
an even stronger migration (217.56 15.0 cells) and tube forma-
tion (2.826 0.27) effect (Fig. 2D, 2E), which is similar to the ob-
servation in endothelial progenitor cells [20]. These data suggest
thatMVs fromASCs, particularly those fromEDM-preconditioned
ASCs, are proangiogenic in vitro. The proliferative effect of MVs
on HUVECs was not observed (control: 0.85 6 0.11; MV:
0.826 0.09; MV-P: 0.906 0.15) (Fig. 2F).
MicroRNA Enriched in ASC-Released MVs
Recent studies have reported that MVs from mesenchymal stem
cells shuttle miRNA between cells [23]. To explore the RNA in
ASC-releasedMVs, isolatedMV-Pwas subjected to smallRNA (fewer
than 200 nucleotides), large RNA, or total RNA extraction and anal-
ysis. Anaverageof3.8ngof small RNAwasharvestedpermicrogram
protein of MV. The majority of the RNA in the MVs was small RNA
(largeRNA:22.0%62.1%; smallRNA:77.8%64.9%),whilemajority
of the RNA in ASCs was large RNA (large RNA: 92.5%6 6.4%; small
RNA:7.5%60.8%) (Fig.3A).BioanalyzerRNAanalysisdemonstrated
that the majority of total RNA in MVs was fewer than 200 nucleo-
tides.A lackof 18S and28S ribosomal RNA indicated that the cellular
contamination was minimal (Fig. 3B). Analysis of small RNA further
revealed that almost all of the small RNA in MVs was in a narrow
range of 10–40 nucleotides, suggesting that miRNA was enriched
in the MVs (Fig. 3C, 3D). Similar RNA size analysis results were ob-
served in MVs in comparison with MV-P.
To confirm the presence of miRNA and inspect the pattern of
miRNA in MVs, miRNA array analysis of the small RNA extracted
fromMV-P was performed. A total of 225miRNAs were detected
and the top 15 abundant miRNAs were listed (supplemental
online Table 1). Based on the extensive reviews of the reported
angiogenesis-regulator miRNAs (AngiomiRs) [43–47], miR-31 is
the only proangiogenic miRNA in the ranking list. Moreover,
the levels of AngiomiRs in MVs and MV-P were examined using
RT-PCR (Fig. 3E). The results demonstrated that miR-31 in MVs
was mostly induced by EDM preconditioning in ASCs. These find-




It has been reported thatmiR-31 is inducedby vascular endothelial
growth factor (VEGF) in HUVECs [48] and upregulated in regener-
ative muscle after hindlimb ischemia [49]. Recently, miR-31 has
been observed to promote endothelial cell migration and angio-
genesis [40, 50]. Our data exhibited that miR-31 levels were
Figure 1. Induction of migration and tube formation of HUVECs by
CdM from adipose-derived stem cells (ASCs). ASCs were incubated in
endothelial basal medium/1% fetal bovine serum (FBS) for 2 days in
the absence (A, B) or presence (C, D) of GW4869, an MV-formation
inhibitor. CdMwas collected andused to treatHUVECs. Cellmigration
(A, C) and tube formation (B, D) assays for treated HUVECs were per-
formed. The endothelial basal medium/1% FBS without cells was in-
cubated in parallel and was used as a control. The CdMwith removal
of MVs via ultracentrifugation was used as CdM-MV free. Represen-
tative imagesof cellmigrationand tube formationaredisplayed. Scale
bar = 200 mm. (A–D): n = 4. p, p, .05 versus CdM; pp, p, .01 versus
0mM.Abbreviations: CdM,conditionedmedium;HUVEC, humanumbil-
ical vein endothelial cell; MV, microvesicle.
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elevated in HUVECs upon treatment with miR-31-enriched MV-P
(1.006 0.05 vs. 2.906 0.22, MV andMV-P, respectively). The el-
evation was reduced when the MV-P was isolated from miR-31-
silenced donor ASCs (1.47 6 0.18) (Fig. 4A). Similarly, MV-P-
induced cell migration (116.3 6 15.8 cells vs. 232.0 6 19.3
cells, MV and MV-P, respectively) and tube formation (1.00 6
0.10 vs. 1.77 6 0.19, MV and MV-P, respectively) were
significantly decreased for migration (154.0 6 9.2 cells) and
tube formation (1.216 0.16) when the MV-P was isolated from
miR-31-silencedASCs (Fig. 4B, 4C). Direct transfection of pre-miR-
31 promoted the tube formation of HUVECs (1.006 0.23 vs.
2.286 0.36) (Fig. 4D). Additionally, the transfection of small RNA
fromMV-P inducedHUVECmigration and tube formation. The in-
duction was decreased when cotransfecting with a commercial
anti-miR-31 (supplemental online Fig. 2A, 2B). These findings sug-
gest that miR-31 contributes to the proangiogenesis induced by
MV-P in vitro.
While most in vitro assays are designed to study a particular
step in the angiogenic conditions, the aortic ring ex vivo assay re-
capitulates all of the key steps in angiogenic processes, including
matrix degradation, cell migration, and proliferation. Here, our
datademonstrated thatMV-Penhanced the sproutingoutgrowth
from aortic rings in comparison with MVs (MV/ZIPmiR-Cont:
1.18 6 0.38; MV-P/ZIPmiR-Cont: 3.32 6 0.36) (Fig. 5A). The
enhancement was significantly inhibited when MV-P was isolated
from miR-31 depleted ASCs (MV-P/ZIPmiR-31: 2.14 6 0.30). A
mouse Matrigel plug assay was also used to inspect the effect of
ASC-released MVs on angiogenesis. Our results revealed that
MVs induced functional vasculature formation, compared with
PBS, as indicated by the red plug appearance and CD31-
positive area on the plug section (1.00 6 0.19 vs. 2.01 6 0.66,
PBS and MV, respectively), and that MV-P exhibited even more
proangiogenic activity than MV (6.04 6 1.11). The effect of
MV-P was attenuated if the MV-P were from miR-31 knockdown
cells (MV-P/ZIPmiR-Cont: 6.186 0.93; MV-P/ZIPmiR-31: 3.546
Figure 3. Analysis of RNA extracted from ASC-released MVs. (A):
Small RNA (fewer than200nucleotides) and largeRNAextracted from
ASCs andASC-releasedMVswere quantified (n = 3– 4). Total RNAwas
set to 100%. (B): Equal amounts of total RNA fromASCs andMVswere
analyzed using Bioanalyzer (Agilent Technologies). 18S and 28S indi-
cated the ribosomal RNA. (C): Small RNA fromMVs was analyzed us-
ing Bioanalyzer. (D): An electropherogram of the lane MV on (C). (E):
Reverse-transcriptase-polymerase chain reaction analysis of miRNA
for small RNA extracted from MV-P. The level of miRNA in MV was
set to 1 (dashed line). U6 was used as an internal control. n = 4.
p, p, .05; pp, p, .01. Abbreviations: ASC, adipose-derived stem cell;
miRNA, microRNA; MV, microvesicle; nt, nucleotide.
Figure 4. miR-31 contributes to the proangiogenesis induced by
MV-P in vitro. (A–C): Adipose-derived stem cells (ASCs) were trans-
duced with lentiviral ZipmiR-31 to silence miR-31. ZipmiR-Cont was
used as a control. MVs andMV-Pwere obtained from the transduced
ASCs and were used to treat HUVECs. The miR-31 content in HUVECs
(A), and the cell migration (B) and tube formation (C) of HUVECswere
determined. (D):HUVECswere transfectedwith commercial pre-miR-
31. A pre-miR-Cont was used as a control. The tube formation of
HUVECs was measured 48 hours after transfection. (A–D): n = 4–5.
p, p, .05; pp, p, .01. Abbreviations: HUVEC, human umbilical vein
endothelial cell; miR-31, microRNA-31; MV, microvesicle; MV-P,
microvesicles from adipose-derived stem cells preconditioned with
endothelial differentiation medium.
Figure 2. Induction of migration and tube formation of HUVECs by
MVs from adipose-derived stem cells (ASCs). (A): Conditioned me-
diumwas subjected to standard serial centrifugation forMV isolation.
The isolated pellet was examined with scanning electron microscopy
(scale bar = 1 mm). (B): ASCs were maintained in growth medium or
preconditioned with endothelial differentiation medium for 4 days.
Afterwashing, the ASCswere then incubated for 2 days in endothelial
basal medium/1% FBS with or without the presence of GW4869.
Western blot analysis of the MVs was performed with Alix, an MV
marker. Each lane represented an MV lysate from 3 3 106 cells.
(C): The protein content of MVs and MV-P from ASCs were deter-
mined. (D–F): HUVECs were treated with 30 mg/ml (protein concen-
tration) MV or MV-P. HUVECs in fresh endothelial basal medium/1%
FBS was used as a control. Cell migration (D), tube formation (E), and
proliferation (F) assaysof theHUVECswereperformedasdescribed in
Material and Methods. (C–F): n = 4. ##, p, .01 versus MV or control;
pp, p , .01 versus control. Abbreviations: HUVEC, human umbilical
vein endothelial cell; MV, microvesicle; MV-P, microvesicles from
adipose-derived stem cells preconditioned with endothelial differ-
entiation medium; OD, optical density.
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0.70) (Fig. 5B). Taken together, wepresent the evidence thatmiR-
31 mediates MV-P induced proangiogenesis ex vivo and in vivo.
FIH1 Is a Target of MV-P-Delivered miR-31 in HUVECs
To further investigate themolecular mechanism ofMV-delivered
miR-31 in HUVECs, the target genes of miR-31 were investigated.
The genes that have been reported as both miR-31 targets
and angiogenesis regulators, so far as we know, include fih1
[34, 51], fat4 [40], tbxa2r [50, 52], tiam1 [53, 54], and rgs4 [55, 56].
Among these genes, only fih1 was downregulated by MV-P in
HUVECs in comparison with that by MVs, while the others pre-
sented no significant difference (Fig. 6A). Indeed, the FIH1 mRNA
levels (1.00 6 0.19 vs. 0.50 6 0.07) and protein levels (1.00 vs.
0.65) were reduced in HUVECs upon the transfection of miR-31
precursor (Fig. 6B, 6C). A conserved miR-31 target site residing
at nucleotides 117–124 and 3 poorly conserved sites at
774–780, 2,789–2,795, and 4,709–4,715 in the FIH1 39-UTR were
predicted by miRNA target prediction websites TargetScan
Human 6.0 (http://www.targetscan.org/vert_60) and PicTar
(http://pictar.mdc-berlin.de) (Fig. 6D; supplemental online Fig.
3A–3C). To experimentally validate the targeting activity, lucifer-
ase reporter constructs, a Luc/FIH1-FL (full-length) containing all
of the 4 sites and a Luc/FIH1-HL (half-length) containing only first
2 sites at nucleotides 117–124 and 774–780, were created (Fig.
6D). Our data showed that the luciferase activity in Luc/FIH1-FL
or Luc/FIH1-HL-transduced HUVECs was similarly suppressed by
miR-31, which suggested that FIH1 was a direct target of miR-
31 in HUVECs and that the actual target sites might be at nucle-
otides 117–124 and/or 774–780 in FIH1 39-UTR. Furthermore, a
mutation at the site 117–124 in FIH1 39-UTRnearly completely re-
stored the luciferase activity, which suggests that miR-31 targets
FIH1 in HUVECs at the conserved nucleoside site 117–124 of 39-
UTR (in the pre-miR-31 transduced group, Luc/blank: 0.98 6
0.08; Luc/FIH1-FL: 0.52 6 0.07; Luc/FIH1-HL: 0.54 6 0.06; Luc/
FIH1-HLmut: 0.946 0.08) (Fig. 6E). As expected, the downregu-
lationof FIH1expression inHUVECsby the treatment ofMV-Pwas
restoredwhenMV-P originated frommiR-31 depleted ASCs (MV/
control: 1.006 0.16; MV/ZIPmiR-Cont: 0.956 0.14; MV/ZIPmiR-
31: 1.046 0.12; MV-P/control: 0.616 0.08; MV-P/ZIPmiR-Cont:
0.68 6 0.04; MV-P/ZIPmiR-31: 1.08 6 0.16) (Fig. 6F, 6G). These
findings suggest that FIH1 may be a direct target of MV-P-
delivered miR-31 in HUVECs.
DISCUSSION
As a cell-based angiogenic therapy, implantation of ASCs is effica-
cious in the ischemic hindlimb/heart animal models mainly
through secretory effects [8, 9]. MVs secreted from stem cells re-
cently have been recognized as a potential alternative therapeu-
tic approach to ischemic diseases [14].Here,wedemonstrate that
ASC-released MVs enhance angiogenesis, and that miR-31 in the
MVs contributes to the induction of angiogenesis by targeting
FIH1 in vascular endothelial cells.
The characterization and proangiogenic effect of ASCs on car-
diovascular repair havebeen recently reviewed [4]. The underlying
mechanism of the proangiogenic effects of ASCs remains unclear.
Although the endothelial differentiation of ASCs is not efficient
and is not considered a the major proangiogenic mechanism,
Figure 5. miR-31 contributes to the proangiogenesis induced by MV-P ex vivo and in vivo. Adipose-derived stem cells (ASCs) were trans-
ducedwith lentiviral ZipmiR-31 to silencemiR-31. ASCs untransduced (control) or transducedwith a ZipmiR-Contwere used as controls.MV
andMV-P were obtained from these ASCs. (A):Mouse aortic rings were collected and treated with variousMVs, as indicated, for 5 days (n =
8). Representative images (upper panel) and a statistical analysis of the outgrowth area of aortic rings (lower panel) for each treatment
condition are displayed. The outgrowth area of aortic rings treated with MV from untransduced cells was set to 1. Scale bar = 100 mm.
(B): PBS, MV, or MV-P was mixed with Matrigel and injected subcutaneously into the flanks of the nude mice. The Matrigel plugs were
harvested 2 weeks postimplantation (n = 6). Upper panel: Representative pictures of the plugs are exhibited. Scale bar = 5 mm. Middle
panel: The sections of the plugs were subject to immunohistochemistry analysis for CD31, an endothelial cell marker, and counterstained
with DAPI. Scale bar = 100mm. Lower panel: Quantification of the CD31-positive area was performed. The positive area in the slide from the
plugs containing PBS was set to 1. p, p, .05; pp, p, .01. Abbreviations: DAPI, 49,6-diamidino-2-phenylindole; miR-31, microRNA-31; MV,
microvesicle; MV-P, microvesicles from adipose-derived stem cells preconditioned with endothelial differentiation medium; PBS,
phosphate-buffered saline.
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preconditioningASCswithEDMisstillobservedtopromoteangiogen-
esis [8,9]. There isagrowingacknowledgment that theproangiogenic
effect of the preconditioned ASCs is mainly a result of cell secre-
tions [9]. Apart from soluble growth factors, cell-released MVs
havebeen identified as a newmechanismof intercellular commu-
nication [22]. MVs are plasma membrane-derived vesicles [21]
released into themicroenvironmentbyvarious cell types, including
stem cells and progenitors [19, 20]. Emerging evidence in MV-
based therapy indicates that MVs released from bone marrow
mesenchymal stem cells can promote angiogenesis in animal
myocardial infarction models [26, 28]. Our data reveal that the
amount of ASC-released MVs is dramatically increased by EDM-
preconditioning. In addition, MVs from EDM-preconditioned
ASCs demonstrate a greater proangiogenic effect in vitro than
the sameamountofMVsfromregular culturedASCs. These findings
suggest that EDMpreconditioning of ASCs enhances both the quan-
tity and theproangiogenic effect of theMVs. In contrast,MVrelease
is reduced by pretreatment of ASCs with GW4869, an inhibitor of
neutral sphingomyelinase that catalyzes the production of plasma
membrane ceramide. Ceramide promotes the sorting and forma-
tion of secretory vesicles frommultivesicular bodies in cells [29]. Al-
though we have not observed an MV-induced cell proliferation,
which may be induced by paracrine growth factors from ASCs,
EDM preconditioning is still beneficial for MVs in cell migration
and tube formation. Other preconditioning methods, such as hyp-
oxia, are also worthwhile for future evaluation.
Figure 6. MV-P suppresses FIH1 expression in human umbilical vein endothelial cells (HUVECs) via the delivery of miR-31. (A): The levels of
predictedmiR-31 targetmRNA inMV orMV-P-treated HUVECswere examinedwith reverse-transcriptase polymerase chain reaction (RT-PCR).
b-actin was used as an internal control. ThemRNA levels inMV-treated HUVECs were set to 1.0 (dashed line) (n = 5). (B, C):HUVECs were trans-
fectedwithpre-miR-Cont (control) or pre-miR-31. ThemRNAandprotein levels of FIH1 in transfectedHUVECsweredeterminedwithRT-PCR (n=
3) (B) andWestern blot (C), respectively. (D): Schematic representation of the luciferase-reporter lentivirus containing insert of FL or HL of FIH1
39-UTR. Four predictive target sites bymiR-31 are shown. Amutation at the site of 117–124 of FIH1 39-UTR is illustrated. The seed site ofmature
miR-31 is highlighted. (E):HUVECswere transfectedwith pre-miR-Cont or pre-miR-31 followed by transduction of indicated lentiviral reporters
the next day. The luciferase activity in HUVECs was determined using luminometry 2 days posttransduction (n = 5). (F): MV and MV-P from
ZIPmiR-31-transduced adipose-derived stem cells (ASCs) were used to treat HUVECs. MV and MV-P from untransduced (control) or ZIPmiR-
Cont-transduced ASCs were used as controls. The protein levels of FIH1 in treated HUVECs were determined using Western blot. b-actin
was used as an internal control. (G): A statistical analysis of the density of the Western blot bands in (F) using Image J software. p, p , .05;
pp, p, .01. Abbreviations: FL, full length; HL, half length; miR-31, microRNA-31; MV, microvesicle; MV-P, microvesicles from adipose-derived
stem cells preconditioned with endothelial differentiation medium; NS, not statistically significant.
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An interesting publication has demonstrated that stem cell-
released MVs/exosomes from healthy people inhibit the growth
of tumor cells, whereas stem cell-released MVs/exosomes from
patients with tumors promote tumor growth [57]. This suggests
the healthy donors as the source of ASCs. Genetic materials are
known to be transferred vertically from parent cell to daughter
cells in the process of mitosis. However, recent findings have
revealed that functional mRNA and miRNA can be transferred
horizontally between cells via the MVs [19, 20, 22]. The concept
of genetic material delivery from MVs to target cells is similar to
the concept of gene delivery from sperm to ovum, but is ubiqui-
tous in physiology, pathology, and pharmacology. Our results
have demonstrated that miRNA is enriched in ASC-released
MVs. There is increasing evidence that miRNA is involved in var-
ious biological processes, including angiogenesis [43–47]. MiRNA
in MVs has been reported to protect the kidney from ischemia-
reperfusion injury [58].
Based on ourmiRNA profiling analysis and AngiomiR analysis,
wehavedemonstrated that the level ofmiR-31 inMVs ismarkedly
upregulatedwhen the donor ASCs are EDMpreconditioned.MiR-
31 is a pleiotropically actingmiRNA and is reported to decrease or
increase cell motility in different cancer cells [34, 54, 55, 59]. This
may be because the miRNA-mRNA target relationship differs
among tissues, cells, and conditions [60].We and other investiga-
tors have shown that miR-31 consistently augments cell migra-
tion in vascular endothelial cells or endothelial progenitor cells
[40, 50, 61]. In addition, miR-31 is elevated in VEGF-treated
HUVECs and ischemic hindlimbs [48, 49]. In patients suffering
from coronary artery disease, overexpressing miR-31 in endothe-
lial progenitor cells rescues their angiogenic abilities both in vitro
and in vivo [50].Our current studydemonstrates thatmiR-31 con-
tributes to MV-P-induced angiogenesis. These findings not only
uncover an underlying molecular mechanism for MV-based an-
giogenic therapy but also suggest a potential strategy to elevate
the angiogenic effect of MVs through miRNA-engineering of MV-
donor cells.
miRNAs are a group of small (21–24 nucleotides), noncoding
RNAs that regulate gene expression by binding to the 39-UTR of
mRNA to repress gene expression [62]. Computational predictive
analysis with TargetScan illustrates that miR-31 has 368 con-
served targets, with a total of 394 broadly conserved sites and
153 poorly conserved sites. Certain genes have been experimen-
tally validated to be the direct targets of miR-31, including fih1 in
cancer cells and keratinocytes [34, 63], fat4 and tbxa2r in 293T
cells [40, 50], and tiam1 and rgs4 in cancer cells [54, 55]. Addition-
ally, all of these genes are reported to be antiangiogenic [40,
51–53, 56]. Among these five genes, only fih1, rgs4, and tbxa2r
are on the predicted list, in which fih1 has the highest aggregate
probability of conserved targeting (PCT). In fact, the PCT score of
fih1 ranks second among those 368 predicted target genes. In this
study, we have validated that FIH1 mRNA is a target of miR-31 in
HUVECsand is repressedbyMVs isolated fromEDM-preconditioned
ASCs. Moreover, we have identified that the target site is at a
broadly conserved domain located at nucleotides 117–124 in
the FIH1 39-UTR. FIH1 is an asparaginyl hydroxylase enzyme that
inhibits the transcriptional activity ofHIF-1, awell-knownproan-
giogenic factor [64, 65]. Taken together, miR-31 may mediate
the proangiogenic effect ofMVs by targeting FIH1 in vascular en-
dothelial cells.
Small RNAs, including antisense, small interfering RNA, and
microRNA, have emerged as promising therapeutic agents
against a wide array of diseases [66]. Effective delivery of these
molecules is crucial to their successful clinical application. MVs
are naturally produced membrane vesicles that circulate in the
bloodstream and have entered the limelight in delivering thera-
peutic nucleic acids, because of their ability to transfer exogenous
miRNAs into target cells. Basedon these aspects,MVsmight bean
attractive alternative in therapeutic angiogenesis with regard to
the durability, stability, and safety of in vivo delivery.
CONCLUSION
This study demonstrates that release of MVs is an important
mechanistic effect of ASCs on angiogenesis. Direct administration
of MVs from ASCs, particularly from EDM-preconditioned ASCs,
promotes angiogenesis. The majority of RNA in MVs is small
RNA, in which miR-31 contributes to MV-triggered angiogenesis
by targeting FIH1 in vascular endothelial cells. These advances
may provide a framework for implantation of engineered MVs
as an alternative approach for the therapy of ischemic diseases.
However, extensive investigation in animalmodels is still required
to proceed with clinical trials.
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6 Szöke K, Brinchmann JE. Concise review:
Therapeutic potential of adipose tissue-derived
angiogeniccells.STEMCELLSTRANSLATIONALMEDICINE
2012;1:658–667.
7 Cronk SM, Kelly-Goss MR, Ray HC et al.
Adipose-derived stem cells from diabetic mice
448 MicroRNA-31 in Microvesicles Promotes Angiogenesis
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
show impaired vascular stabilization in amurine
model of diabetic retinopathy. STEMCELLS TRANS-
LATIONAL MEDICINE 2015;4:459–467.
8 MiranvilleA,HeeschenC, SengenèsC et al.
Improvement of postnatal neovascularization
byhumanadipose tissue-derivedstemcells. Cir-
culation 2004;110:349–355.
9 Nakagami H, Maeda K, Morishita R et al.
Novel autologous cell therapy in ischemic limb
disease through growth factor secretion by
cultured adipose tissue-derived stromal
cells. Arterioscler Thromb Vasc Biol 2005;
25:2542–2547.
10 ValinaC, Pinkernell K, SongYHetal. Intra-
coronary administration of autologous adipose
tissue-derived stem cells improves left ventric-
ular function, perfusion, and remodelling after
acute myocardial infarction. Eur Heart J 2007;
28:2667–2677.
11 Camussi G, Deregibus MC, Bruno S et al.
Exosomes/microvesicles as a mechanism of
cell-to-cell communication. Kidney Int 2010;
78:838–848.
12 Raposo G, Stoorvogel W. Extracellular
vesicles: Exosomes, microvesicles, and friends.
J Cell Biol 2013;200:373–383.
13 Martinez MC, Andriantsitohaina R. Mi-
croparticles in angiogenesis: Therapeutic po-
tential. Circ Res 2011;109:110–119.
14 Ratajczak MZ, Kucia M, Jadczyk T et al.
Pivotal role of paracrine effects in stem cell ther-
apies in regenerativemedicine: Canwe translate
stem cell-secreted paracrine factors and micro-
vesicles into better therapeutic strategies? Leu-
kemia 2012;26:1166–1173.
15 Lopatina T, Bruno S, Tetta C et al.
Platelet-derived growth factor regulates the
secretion of extracellular vesicles by adipose
mesenchymal stem cells and enhances their
angiogenic potential. Cell Commun Signal
2014;12:26.
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43 Suárez Y, Sessa WC. MicroRNAs as novel
regulators of angiogenesis. Circ Res 2009;104:
442–454.
44 Wang S, Olson EN. AngiomiRs–key regu-
lators of angiogenesis. Curr Opin Genet Dev
2009;19:205–211.
45 Chang SH, Hla T. Gene regulation by RNA
binding proteins and microRNAs in angiogene-
sis. Trends Mol Med 2011;17:650–658.
46 Patella F, Rainaldi G.MicroRNAsmediate
metabolic stresses and angiogenesis. Cell Mol
Life Sci 2012;69:1049–1065.
47 Thum T. MicroRNA therapeutics in car-
diovascular medicine. EMBO Mol Med 2012;4:
3–14.
48 Suárez Y, Fernández-Hernando C, Yu J
et al. Dicer-dependent endothelial micro-
RNAs are necessary for postnatal angiogen-
esis. Proc Natl Acad Sci USA 2008;105:
14082–14087.
49 Greco S, De Simone M, Colussi C et al.
Commonmicro-RNAsignature in skeletalmuscle
damage and regeneration induced by Duchenne
muscular dystrophy and acute ischemia. FASEB J
2009;23:3335–3346.
50 Wang HW, Huang TS, Lo HH et al. Defi-
ciency of the microRNA-31-microRNA-720 path-
way in the plasma and endothelial progenitor
cells from patients with coronary artery dis-
ease. Arterioscler Thromb Vasc Biol 2014;34:
857–869.
51 Huang M, Nguyen P, Jia F et al. Double
knockdown of prolyl hydroxylase and factor-
inhibiting hypoxia-inducible factor with nonviral
minicircle gene therapy enhances stem cell
mobilization and angiogenesis after myocar-
dial infarction. Circulation 2011;124(suppl):
S46–S54.
52 Ashton AW, Cheng Y, Helisch A et al.
Thromboxane A2 receptor agonists antagonize
the proangiogenic effects of fibroblast growth
factor-2: Role of receptor internalization,
thrombospondin-1, and alpha(v)beta3. Circ
Res 2004;94:735–742.
53 Lee SH, Kunz J, Lin SH et al. 16-kDa pro-
lactin inhibits endothelial cell migration by
down-regulating the Ras-Tiam1-Rac1-Pak1
Kang, Jones, Naddell et al. 449
www.StemCellsTM.com ©AlphaMed Press 2016
signaling pathway. Cancer Res 2007;67:
11045–11053.
54 Cottonham CL, Kaneko S, Xu L. miR-21
and miR-31 converge on TIAM1 to regulate mi-
gration and invasion of colon carcinoma cells.
J Biol Chem 2010;285:35293–35302.
55 Zhang T, Wang Q, Zhao D et al. The
oncogenetic role of microRNA-31 as a po-
tential biomarker in oesophageal squamous
cell carcinoma. Clin Sci (Lond) 2011;121:
437–447.
56 Jaba IM, Zhuang ZW, Li N et al. NO trig-
gers RGS4 degradation to coordinate angiogen-
esis and cardiomyocyte growth. J Clin Invest
2013;123:1718–1731.
57 Roccaro AM, Sacco A, Maiso P et al. BM
mesenchymal stromal cell-derived exosomes
facilitate multiple myeloma progression. J Clin
Invest 2013;123:1542–1555.
58 Cantaluppi V, Gatti S, Medica D et al.
Microvesicles derived fromendothelial progen-
itor cells protect the kidney from ischemia-
reperfusion injury by microRNA-dependent
reprogramming of resident renal cells. Kidney
Int 2012;82:412–427.
59 Valastyan S, Reinhardt F, Benaich N et al.
A pleiotropically acting microRNA, miR-31,
inhibits breast cancer metastasis [retracted
Cell. 2015 Apr 9;161(2):417]. Cell 2009;137:
1032–1046.
60 KrekA,GrünD, PoyMNet al. Combinato-
rial microRNA target predictions. Nat Genet
2005;37:495–500.
61 Tsai YH, WuMF,Wu YH et al. TheM type
K15proteinofKaposi’s sarcoma-associatedher-
pesvirus regulates microRNA expression via its
SH2-binding motif to induce cell migration
and invasion. J Virol 2009;83:622–632.
62 Bartel DP. MicroRNAs: Genomics, bio-
genesis, mechanism, and function. Cell 2004;
116:281–297.
63 Peng H, Kaplan N, Hamanaka RB et al.
microRNA-31/factor-inhibiting hypoxia-inducible
factor 1 nexus regulates keratinocyte differen-
tiation. Proc Natl Acad Sci USA 2012;109:
14030–14034.
64 Lando D, Peet DJ, Gorman JJ et al. FIH-1
is an asparaginyl hydroxylase enzyme that regu-
lates the transcriptional activity of hypoxia-
inducible factor.GenesDev2002;16:1466–1471.
65 Rey S, Semenza GL. Hypoxia-inducible
factor-1-dependentmechanismsof vasculariza-
tion and vascular remodelling. Cardiovasc Res
2010;86:236–242.
66 Castanotto D, Rossi JJ. The promises and
pitfalls of RNA-interference-based therapeu-
tics. Nature 2009;457:426–433.
See www.StemCellsTM.com for supporting information available online.
450 MicroRNA-31 in Microvesicles Promotes Angiogenesis
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
